Italian consensus puts rare epilepsies on a multidisciplinary footing
Rare epilepsies rarely behave like one disease. They span heterogeneous genetic, structural, and developmental syndromes, often with seizure patterns that change over time and with outcomes that extend far beyond convulsions alone. A national Italian consensus published in Epilepsia Open argues that care for these disorders has to reflect that complexity, not flatten it into a generic epilepsy pathway.
The working group used a modified Delphi process to convert expert judgment and patient advocacy input into a set of agreed statements on contentious issues in rare epilepsies and developmental and epileptic encephalopathies (DEEs). The effort brought together a scientific board of 20 physicians and 4 patient advocacy representatives, followed by a 32-member panel drawn from different regions of Italy. Consensus required an average score of at least 7 across a two-round voting process.
Sixteen statements reached consensus. The pattern of agreement matters because it places epidemiology, early treatment, and multidisciplinary follow-up at the center of management rather than treating seizure suppression as the only endpoint.
Early classification drives treatment choices and prognosis
Etiology emerged as one of the most important determinants of therapeutic strategy and outcome prediction. In rare epilepsies, the cause is not a background label; it shapes the expected seizure burden, the likelihood of developmental impairment, and the probability that standard antiseizure drugs will be enough. Genetic, metabolic, and structural causes can each point toward different interventions, and the consensus reflects that bedside reality.
Prolonged seizures and tonic-clonic seizures drew particular concern. Their clinical weight is obvious: prolonged convulsive events increase acute danger, strain caregivers, and can mark a more severe disease course. In children and adults living with DEEs, repeated convulsive seizures can also obscure the broader picture of neurodevelopmental decline, behavior, sleep disruption, and family burden. A management strategy that waits for repeated crises before changing course risks missing the window when seizure networks and developmental trajectories are still modifiable.
Early use of specific drugs and non-pharmacological interventions was judged important in the treatment algorithm for DEEs. This is a practical endorsement of acting on syndrome-level knowledge instead of cycling through therapies after months of uncontrolled seizures. In disorders where epileptogenesis is tied to a broader developmental brain disorder, delaying targeted therapy can mean continued network injury, lost developmental opportunity, and escalating caregiver stress.
The consensus places non-seizure outcomes inside routine epilepsy care
A single sentence in an epilepsy clinic can sound like progress when seizures are fewer, yet that may miss what families experience day to day. The Italian panel gave clear weight to non-seizure outcomes in adolescence and adulthood, a sign that the field is moving beyond seizure counts as the only marker of success.
Adolescence and adult life bring different burdens: education, employment, autonomy, mood, sleep, social participation, and the long shadow of neurocognitive disability. For people with rare epilepsies, these domains can be more relevant to quality of life than a modest change in seizure frequency. The consensus therefore supports a broader, more longitudinal model of care, one that includes rehabilitation, psychosocial support, school and workplace planning, and transition services as part of routine practice rather than optional extras.
Multidisciplinary care was judged essential. That conclusion is hard to overstate in a field where a neurologist alone cannot address the full spectrum of needs. Neuropediatricians, neurologists, epilepsy surgeons, neuropsychologists, rehabilitation specialists, genetic counselors, and social support professionals all have a role, and patient advocacy representatives added an additional layer of real-world perspective to the process. The result is a care model that mirrors the disorder: layered, dynamic, and dependent on expertise from multiple disciplines.
Epidemiology remains a major blind spot
One of the clearest areas of agreement concerned the need for epidemiologic studies to determine the true prevalence of rare epilepsies. Without accurate prevalence estimates, health systems cannot plan specialty services, allocate diagnostic resources, or build referral networks at the scale needed for these disorders.
This gap has concrete consequences. Underestimation can leave families navigating delayed diagnosis, fragmented care, and limited access to advanced testing or syndrome-specific treatment. It also makes it harder for policymakers to justify specialized programs for rare disease populations, where the numerical burden may be modest but the clinical complexity is high. Epidemiology is not only a research exercise here; it is a prerequisite for service design.
The consensus also reflects a broader shift in rare epilepsy care toward organized pathways rather than isolated encounters. Clinicians working in this area need a framework that can handle diagnostic uncertainty, evolving phenotype, and transition from pediatric to adult services without losing continuity. The Italian panel’s statements push in that direction.
Patient advocacy was built into the process
The Delphi structure included patient advocacy representatives at the table from the start. That matters in rare epilepsies because lived experience often reveals what formal outcomes miss: the burden of nocturnal seizures on families, the pressure of long diagnostic odysseys, the exhaustion of repeated medication changes, and the social consequences of developmental impairment.
Their involvement likely helped keep the discussion focused on integrated and social care in addition to pharmacology. Rare epilepsy management is not only about choosing the next antiseizure drug. It is about aligning medical decisions with family capacity, developmental stage, educational needs, and long-term support requirements.
The consensus does not claim to settle every disputed issue in the field. It does, however, establish a national framework that prioritizes etiology, early syndrome-specific intervention, and multidisciplinary follow-up for rare epilepsies and DEEs. The remaining challenge is more structural than conceptual: translating these statements into measurable access to expert centers, better prevalence data, and treatment pathways that actually reach patients before disability accumulates.